Clinical Trials Logo

Clinical Trial Summary

A phase II randomized clinical trial was conducted to determine whether etoricoxib could prevent or ameliorate the incidence and/or severity of docetaxel-induced acute pain syndrome. We also aimed to determine if there are any improvement of the late-onset peripheral neuropathy as well as quality of life with prophylactic etoricoxib for breast cancer patients who receive docetaxel chemotherapy.


Clinical Trial Description

Docetaxel plays a key role in reducing the recurrence of early-stage breast cancer as well as improving survival outcomes of advanced breast cancer patients, but it causes a variety of adverse events, including myalgia and arthralgia, peripheral neuropathy, febrile neutropenia, and hypersensitivity reactions and so on. The myalgia and arthralgia induced by docetaxel, which have been together referred to as taxane-associated acute pain syndrome (T-APS), were reported to occur in 3.6% to 70% of patients, and the symptoms usually occurred 24-48 hours after docetaxel infusion and lasted for 3-5 days. Previous studies found that patients who experienced myalgia and arthralgia due to docetaxel administration were more likely to have chronic peripheral neuropathy, which supported that T-APS could be a form of neurologic toxicity. T-APS may significantly influence patients' sleep and daily life, and even caused discontinuation of chemotherapy. Therefore, it is clinically meaningful to explore some prophylactic drugs for the T-APS. Previous studies had used glutamine, corticosteroids, Shakuyaku-Kanzo-To (a Japanese herb), and gabapentin to prevent paclitaxel-induced myalgia and arthralgia, but failed to provide enough evidence for clinical practice. Etoricoxib, a selective COX-2 inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) that has showed comparable efficacy in acute and chronic pain, with fewer gastrointestinal (GI) adverse events compared with traditional NSAIDs. Therefore, we conducted a phase II randomized clinical trial to investigate whether etoricoxib could prevent or ameliorate the incidence and/or severity of docetaxel-induced acute pain syndrome. We also aimed to determine if there are any improvement of the late-onset peripheral neuropathy as well as quality of life with prophylactic etoricoxib for breast cancer patients who receive docetaxel chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04565600
Study type Interventional
Source Guangdong Provincial People's Hospital
Contact
Status Completed
Phase Phase 2
Start date March 1, 2020
Completion date June 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT03793790 - The Role of Learning in Nocebo Hyperalgesia N/A
Completed NCT04527770 - Midazolam Versus Dexamethasone as an Adjuvant to Local Anesthetics in the Ultrasound Guided Hydrodissection of Median Nerve for Treatment of Carpal Tunnel Syndrome Patients N/A
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Withdrawn NCT03707444 - A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer
Recruiting NCT03498976 - RFp on Suprascapular N. Versus RFp on Suprascapular N. and Circumflex in the Treatment of Painful Shoulder N/A
Recruiting NCT04299893 - Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) Phase 2/Phase 3
Completed NCT04625504 - Investigating Biological Targets, Markers, and Intervention for Chronic Pain N/A
Recruiting NCT06072001 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06071962 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06072573 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06071988 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Recruiting NCT06072560 - Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06071975 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06071949 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06071936 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Completed NCT05811455 - Comparative Effects of Aerobic Exercises and Progressive Muscle Relaxation Exercises on Pain and Quality of Life N/A
Completed NCT03755817 - Efficacy Assessment of SCENAR Device on Common Spinal Pain Syndrome N/A
Active, not recruiting NCT06010381 - Muscle Energy Technique Versus Maitland Mobilization on Shoulder Pain and Disability N/A
Terminated NCT03421951 - Change in Pain and Quality of Life Following SCS for Chronic Pain
Recruiting NCT05834725 - Resilience Coaching for Adolescents With Chronic Musculoskeletal Pain N/A